Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Keyphrases
Pediatric Patients
100%
Tyrosine Kinase Inhibitor
100%
B-CLL
100%
Multicenter Retrospective Study
100%
BCR/ABL Fusion Gene
100%
Minimal Residual Disease
62%
Event-free Survival
50%
Hematopoietic Stem Cell Transplantation
50%
Annualized Relapse Rate
37%
ABL2
37%
Newly Diagnosed
37%
Induction Therapy
37%
PDGFRB Fusion
37%
5-year Survival
25%
ABL1
25%
Baseline Characteristics
25%
Ponte
25%
Pacific Studies
25%
Asia-Pacific
25%
Colony-stimulating Factor 1 Receptor (CSF1R)
25%
Clinical Trials
12%
Poor Outcome
12%
Pediatric Cancer
12%
Acute Lymphoblastic Leukemia
12%
Dutch
12%
Fusion Gene
12%
Potential Gains
12%
High Risk
12%
Overall Survival
12%
Hazard Ratio
12%
Complete Remission
12%
Blood Cancer
12%
Early Death
12%
Chemotherapy Regimen
12%
Rotterdam
12%
Early Treatment
12%
Australia
12%
Treatment-related Mortality
12%
PAX5
12%
North America
12%
BCR-ABL1
12%
CDKN2A Deletion
12%
Treatment Outcome
12%
Patient Characteristics
12%
Prednisone
12%
National Cancer Institute
12%
Year of Diagnosis
12%
Kaplan-Meier Method
12%
Multidrug Chemotherapy
12%
First Remission
12%
Tyrosine Kinase Inhibitor Treatment
12%
Risk Model
12%
Mortality Response
12%
Cancro
12%
North Asia
12%
European Studies
12%
National Institutes of Health
12%
Leukaemic Cells
12%
American Pacific
12%
European North
12%
Non-response
12%
Cancer Societies
12%
Treatment Lines
12%
Unfavorable Outcome
12%
North American Studies
12%
Medicine and Dentistry
B Cell
100%
Acute Lymphoblastic Leukemia
100%
Pediatrics Patient
100%
Tyrosine-Kinase Inhibitor
100%
Retrospective Cohort Study
100%
Minimal Residual Disease
62%
Event Free Survival
50%
Hematopoietic Stem Cell Transplantation
50%
Malignant Neoplasm
37%
Cumulative Incidence
37%
Overall Survival
37%
Chemotherapy
25%
Clinical Trial
12%
Pediatric Cancer
12%
Fusion Gene
12%
Hazard Ratio
12%
Hematological Cancer
12%
Kaplan Meier Method
12%
Prednisone
12%
Treatment Outcome
12%
Cyclin Dependent Kinase Inhibitor 2A
12%